slide1
Download
Skip this Video
Download Presentation
HER2-Targeted Therapy

Loading in 2 Seconds...

play fullscreen
1 / 36

HER2-Targeted Therapy - PowerPoint PPT Presentation


  • 187 Views
  • Uploaded on

HER2-Targeted Therapy. THE PROBLEM WITH ‘OFF TARGET’ TOXICITY TO THE HEART Melinda Telli, MD Instructor in Medicine Stanford University 9/12/2008. Overview. Heart Failure & the Elderly Updated ACC/AHA Heart Failure Staging The Trastuzumab Story Risk Versus Benefit Analysis.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'HER2-Targeted Therapy' - ena


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
her2 targeted therapy
HER2-Targeted Therapy

THE PROBLEM WITH ‘OFF TARGET’

TOXICITY TO THE HEART

Melinda Telli, MD

Instructor in Medicine

Stanford University

9/12/2008

overview
Overview
  • Heart Failure & the Elderly
  • Updated ACC/AHA Heart Failure Staging
  • The Trastuzumab Story
  • Risk Versus Benefit Analysis
cancer patients living longer
Cancer patients living longer

Long-term toxicities of therapy take on greater significance

American Cancer Society 2004

slide6

Cardiovascular versus Cancer Deaths by Age

United States: 2004; Source: NCHS and NHLBI

slide7

Heart failure is primarily a disease of the elderly

NHANES: 1999-2004Source: NCHS and NHLBI.

slide8

Impact of Heart Failure

  • Approximately 80% of patients hospitalized with heart failure are over 65
  • Most common Medicare diagnosis-related group (DRG)
  • One of the largest Medicare expenditures
slide9

Taking the Congestion

Out of Heart Failure

Stages in the evolution

of Heart Failure

HF Risk Factors

No Heart disease

No symptoms

A

B

Heart disease

No symptoms

Asymptomatic

LV dysfunction

C

Prior or current

HF Symptoms

D

Refractory

HF symptoms

Hunt SA, et al: AHA / ACC HF guidelines 2001

slide10

Trastuzumab, Anthracyclines

A

Hypertension

Diabetes, Hyperchol.

Family Hx

Cardiotoxins

Clinical Stages in the

Evolution

of Heart Failure

B

Heart disease

(any)

4% in NSABP B-31

Asymptomatic

LV dysfunction

C

Dyspnea, Fatigue

Reduced exercise

tolerance

14% in NSABP B-31

D

Marked symptoms

at rest despite

max. therapy

Hunt SA, et al: AHA / ACC HF guidelines 2001

slide11

Treat risk factors

Avoid toxics

ACE-i (selected pts)

A

Stages in the Evolution

of Heart Failure

Treatment

B

ACE-i

 blockers

In selected

patients

C

ACE-i

 blockers

Diuretics / Digitalis

Class I indication for patients with asymptomatic LV dysfunctoin

D

Palliative therapy

Mech. Assist device

Heart Transplant

tyrosine kinase targeted therapies the list keeps growing
Monoclonal Antibodies

Trastuzumab

Bevacizumab

Cetuximab

Panitumumab

Small Molecule TKIs

Imatinib

Gefitinib

Erlotinib

Lapatinib

Sorafenib

Sunitinib

Dasatinib

Tyrosine Kinase Targeted TherapiesThe list keeps growing
the heartbreak of success
The Heartbreak of Success

Reports of heart failure begin

to emerge

Trastuzumab

Imatinib

LAPATINIB

Sunitinib

Others???

determining extent of the problem
Determining Extent of the Problem
  • Many trials lack prospective cardiac monitoring
  • Heart failure difficult to diagnose in the cancer patient
  • Patients with cardiac comorbidities often excluded
  • Lack of standardized cardiotoxicity reporting
  • Focus on the most severe cardiac safety outcomes
slide15
How accurate is physician reporting of chemotherapy adverse effects?A COMPARISON OF PATIENT REPORTED & PHYSICIAN REPORTED SYMPTOMS

17

60

70

30

77

65

65

38

80

60

Percentage

40

20

0

Pain

Fatigue

Insomnia

Anorexia

Nausea/

Vomiting

Dyspnea

Diarrhea

Constipation

Physician missed

Physician identified

Fromme et al: J Clin Oncol 2004; 22(17)3485-3490.

independent cardiac review evaluation committee crec
Independent Cardiac Review & Evaluation Committee (CREC)

Seidman A et al: J Clin Oncol 2002; 20:1215-21.

a two hit model of trastuzumab induced cardiotoxicity
A ‘two-hit’ model of trastuzumab-induced cardiotoxicity
  • Trastuzumab -> loss of ErbB2-mediated signaling
    • Interferes with ability of the heart to respond to stress
  • When faced with subsequent stress -> ErbB2-deficient hearts are more susceptible to the cardiotoxic effects of the stressor
reversible or just treatment responsive

90

80

70

60

50

40

30

20

10

0

Mean LVEF (%)

Prior to

Trastuzumab

Therapy

(n = 38)

Following

Standard Therapy

for Heart Failure

(n = 32)

Following

Trastuzumab

Rechallenge

(n = 25)

Following

Trastuzumab

Therapy

(n = 37)

Reversible or Just Treatment Responsive?

Durand JB, et al: J Clin Oncol 2005;23:7820-7826

adjuvant trastuzumab trials major improvements in dfs
Adjuvant Trastuzumab TrialsMAJOR IMPROVEMENTS IN DFS

Telli ML et al: J Clin Oncol 25:3525-3533, 2007

adjuvant trastuzumab trials
Adjuvant Trastuzumab Trials

NSABP B-31 & NCCTG N-9831

AC x 4 > Taxol x 4

AC x 4  Taxol x 4H x 52

HERA

At least 4 cycles chemo  Observation vs. H 1yr vs. H 2yrs

BCIRG 006

AC x 4  Docetaxel x 4

AC x 4  Docetaxel x 4  H x 52

Docetaxel + Carboplatin x 6 + H x 52 (“TCH”)

adjuvant trastuzumab trials24
Adjuvant Trastuzumab Trials

FinHER

Docetaxel x 3 + H x 9 wks > FEC x 3

Docetaxel x 3 > FEC x 3

Vinorelbine x 3 + H x 9 wks > FEC x 3

Vinorelbine x 3 > FEC x 3

prospective cardiac monitoring in the adjuvant trials
Prospective Cardiac Monitoring in the Adjuvant Trials
  • Designed to minimize significant cardiotoxicity
  • Significant cardiac comorbidities excluded
  • Trials required normal baseline LVEF
  • Protocol specified cardiac safety analyses
cardiac monitoring strategy nsabp b 31 ncctg n9831
Cardiac Monitoring StrategyNSABP B-31 &NCCTG N9831

* Treatment was discontinued if LVEF did not recover to a level above hold

criteria after treatment stopped for 4 weeks

detailed cardiac data from nsabp b 31 cardiac events
Detailed Cardiac Data from NSABP B-31 Cardiac Events

Tan Chiu et al: J Clin Oncol 2005;23:7811-9.

additional b 31 cardiotoxicity data
Additional B-31 Cardiotoxicity Data
  • Symptomatic CHF not meeting criteria for a cardiac event:

C: 1%

H: 5.1%

  • 14% discontinued trastuzumab secondary toasymptomatic declines in LVEF

Tan Chiu et al: J Clin Oncol 2005;23:7811-9

follow up lvef after diagnosis of cardiotoxicity
Follow-up LVEF after Diagnosis of Cardiotoxicity

Cardiac Event Symptoms of CHF Asymptomatic ↓ LVEF

Tan Chiu et al: J Clin Oncol 2005;23:7811-9

nsabp b 31 analysis of benefits vs risks at 3 years
NSABP B-31 Analysis of Benefits vs. Risks at 3 years

Telli ML et al: J Clin Oncol 25:3525-3533, 2007

nsabp b 31 cardiac risk score
NSABP B-31Cardiac Risk Score

Factors associated with risk of developing a cardiac

event:

  • Use of hypertensive medications
  • Age >49
  • Baseline LVEF <54

Risk Score = 100 x 7.4(0.03 x Age) – (0.10 + baseline LVEF) + (0.68 x C)

4.82

C = HTN medication status: none = 0; yes = 1

Rostagi P, Adjuvant Breast Oral Session, ASCO 2007

nsabp b 31 cardiac risk score34

Cardiac Risk Score = 82

3-year predicted incidence of symptomatic heart failure/cardiac death 10%

NSABP B-31Cardiac Risk Score

Example:

62 yo woman on antihypertensive medication

Baseline LVEF = 60%

future directions
Future Directions

PREVENTION

  • Pre-emptive use of ACE inhibitors or beta-blockers in may prevent cardiotoxicity

EARLY DETECTION

  • Cardiac biomarkers may help identify high risk patients
    • Troponin
    • BNP
slide36

Conclusions: Trastuzumab

  • Symptomatic heart failure in up to 4% in adjuvant trials
  • Asymptomatic declines in LVEF much more common
  • Less cardiotoxicity with non-anthracycline containing TCH regimen
  • No cardiotoxicity observed in FinHER
  • Need to consider absolute benefits vs. risks
ad